GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (STU:6GJ) » Definitions » Float Percentage Of Total Shares Outstanding

Glaukos (STU:6GJ) Float Percentage Of Total Shares Outstanding : 58.81% (As of Jun. 23, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Glaukos Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Glaukos's float shares is 29.62 Mil. Glaukos's total shares outstanding is 50.37 Mil. Glaukos's float percentage of total shares outstanding is 58.81%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Glaukos's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Glaukos's Institutional Ownership is 87.53%.


Glaukos Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Glaukos's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=29.62/50.37
=58.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glaukos (STU:6GJ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (STU:6GJ) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Glaukos (STU:6GJ) Headlines

No Headlines